Literature DB >> 14621136

Acute physiologic and chronic histologic changes in rats and mice exposed to the unique hallucinogen salvinorin A.

Mark Mowry1, Michael Mosher, Wayne Briner.   

Abstract

Salvinorin A is a unique hallucinogen that is seeing increased use in humans. It is not currently a controlled substance and is used as a legal alternative to controlled substances. Usually smoked or buccally absorbed by chewing, doses of approximately 200 mcg can produce profound hallucinogenic effects of short duration. The mechanism of action of salvinorin A is at the kappa-opioid receptor. Little data is available on the medical effects of this substance so animal studies were undertaken to explore the acute toxic effects of this substance in rats and the chronic effects in mice. Rats were anesthetized and administered salvinorin A at 1600 mcg/kg or vehicle. Recordings were made of galvanic skin response, EKG, temperature, and pulse pressure for 100 minutes. Mice were chronically exposed to vehicle or 400, 800, 1600, 3200, or 6400 mcg/kg of salvinorin A for two weeks. After exposure the animals were sacrificed and brain, heart, kidney, bone marrow, blood and spleen were removed, fixed, sectioned, stained and examined by light microscopy. No effects were seen on cardiac conduction, temperature, or galvanic skin response. A nonsignificant rise was seen in pulse pressure. Histologic studies of spleen, blood, brain, liver, kidney, and bone marrow did not find any significant histologic changes at any of the doses examined. These data suggests that the toxicity of salvinorin A is relatively low, even at doses many times greater than what humans are exposed to. However, further studies should be done on blood pressure effects. The psychological impact of this potent hallucinogen should also be investigated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14621136     DOI: 10.1080/02791072.2003.10400021

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  14 in total

1.  A combined ligand-based and target-based drug design approach for G-protein coupled receptors: application to salvinorin A, a selective kappa opioid receptor agonist.

Authors:  Nidhi Singh; Gwénaël Chevé; David M Ferguson; Christopher R McCurdy
Journal:  J Comput Aided Mol Des       Date:  2006-09-29       Impact factor: 3.686

2.  Novel Drugs of Abuse: A Snapshot of an Evolving Marketplace.

Authors:  Ryan Vandrey; Matthew W Johnson; Patrick S Johnson; Miral A Khalil
Journal:  Adolesc Psychiatry (Hilversum)       Date:  2013-04

3.  Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement.

Authors:  Daniela Braida; Valeria Limonta; Simona Pegorini; Alessia Zani; Chiara Guerini-Rocco; Enzo Gori; Mariaelvina Sala
Journal:  Psychopharmacology (Berl)       Date:  2007-01-12       Impact factor: 4.530

Review 4.  Perspectives on zebrafish models of hallucinogenic drugs and related psychotropic compounds.

Authors:  Nikhil Neelkantan; Alina Mikhaylova; Adam Michael Stewart; Raymond Arnold; Visar Gjeloshi; Divya Kondaveeti; Manoj K Poudel; Allan V Kalueff
Journal:  ACS Chem Neurosci       Date:  2013-08-06       Impact factor: 4.418

5.  Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum.

Authors:  Matthew W Johnson; Katherine A MacLean; Chad J Reissig; Thomas E Prisinzano; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2010-12-04       Impact factor: 4.492

6.  Acute and post-acute behavioral and psychological effects of salvinorin A in humans.

Authors:  Peter H Addy
Journal:  Psychopharmacology (Berl)       Date:  2011-09-08       Impact factor: 4.530

7.  Synthetic studies of neoclerodane diterpenes from Salvia divinorum: role of the furan in affinity for opioid receptors.

Authors:  Denise S Simpson; Kimberly M Lovell; Anthony Lozama; Nina Han; Victor W Day; Christina M Dersch; Richard B Rothman; Thomas E Prisinzano
Journal:  Org Biomol Chem       Date:  2009-07-14       Impact factor: 3.876

8.  Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents.

Authors:  Daniela Braida; Valeria Capurro; Alessia Zani; Tiziana Rubino; Daniela Viganò; Daniela Parolaro; Mariaelvina Sala
Journal:  Br J Pharmacol       Date:  2009-05-05       Impact factor: 8.739

9.  Pharmacology and anti-addiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A.

Authors:  B Simonson; A S Morani; A W M Ewald; L Walker; N Kumar; D Simpson; J H Miller; T E Prisinzano; B M Kivell
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

10.  Salvinorin A administration after global cerebral hypoxia/ischemia preserves cerebrovascular autoregulation via kappa opioid receptor in piglets.

Authors:  Zhenhong Wang; Nan Ma; John Riley; William M Armstead; Renyu Liu
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.